New combo therapy aims to boost immune attack on eye cancer
NCT ID NCT07203391
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether adding a new drug called roginolisib to the existing treatment tebentafusp can help people with advanced uveal melanoma, a rare eye cancer. The study involves 8 adults whose cancer has spread and who are already on tebentafusp. The main goal is to find a safe dose and see if the combination helps the immune system stay active longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tebentafusp and roginolisib
- What this could lead to
- If this combination works, it could offer a new treatment option for advanced uveal melanoma by helping the immune system fight the cancer longer.
- What could go wrong
- This is a very early Phase 1 trial with only 8 participants, so it is primarily testing safety and dosing. The combination may not be effective or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alfred Hospital
NOT_YET_RECRUITINGMelbourne, Victoria, Australia
-
St Vincents Hospital
RECRUITINGSydney, New South Wales, 2010, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.